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Abstract
BACKGROUND: The relationship between socioeconomic status and CA-CDI incidence has not
been examined. I hypothesize that there will be higher incidence rates of CA-CDI in areas of
higher socioeconomic status, where individuals are more likely to have health insurance, better
access to care and are more educated.
METHODS: Community onset (CO) cases from Emerging Infections program surveillance were
defined as those with a CDI positive specimen sample less than four days after admission to a
health care facility. Community associated CO cases were defined as those that did not have a
healthcare exposure in the prior three months. Unadjusted CA-CDI incidence rates by sex, race,
spatial location, and poverty rate were calculated. A spatial analysis of CA-CDI was conducted in
SatScan9.3. Using Epi Info 7, chi-square test for trend was conducted to assess the relationship
between CDI incidence and percent below poverty by census tract.
RESULTS: 1106 cases of CA-CDI occurred in New Haven County from 2011 to 2013. CA-CDI
incidence was between 44 and 50 cases per 100,000 population for these three years. When
cases for all three years were aggregated, a significant trend was revealed, where CA-CDI
incidence increased as census tract poverty decreased. Similarly, age 5-17 CA-CDI incidence
decreased as census tract poverty increased, but age 45-64 CA-CDI incidence increased as
census tract poverty increased. A significant spatial cluster was revealed near Wallingford.
CONCLUSIONS: Incidence appears to be highest in the census tracts with the highest
socioeconomic status, but data were inconclusive. Adjusted rates as well as additional
surveillance data will help reveal the true relationship between socioeconomic status and CACDI. Spatial clusters will help direct future interventions that aim to reduce CA-CDI incidence.
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Introduction
Clostridium difficile infection (CDI) is a growing public health concern. Traditionally CDI was
thought to be nosocomial in origin, since it was the leading cause of infectious diarrhea and
pseudomembranous colitis in a healthcare setting (Barbut, Corthier et al. 1996). In the last
decade, the epidemiology of CDI changed. Researchers in Quebec examined surveillance data
and suggested that incidence had increased from 35.6 cases per 100,000 population in 1991 to
156.3 cases per 100,000 population in 2003 for that catchment area (Pépin, Valiquette et al.
2004, Loo, Poirier et al. 2005). The increased incidence was not limited to Canada, as outbreaks
were also reported in the USA (Dallal, Harbrecht et al. 2002, McDonald, Killgore et al. 2005). In
these outbreaks, a larger proportion of infections progressed to more severe symptoms, such
as toxic megacolon, intestinal perforation, necessity of colectomy, and death (Dallal, Harbrecht
et al. 2002, Pépin, Valiquette et al. 2004, McDonald, Killgore et al. 2005).
A large proportion of infections that occurred in outbreaks across North America were
caused by the North American Pulse Field Gel Electrophoresis Type 1 (NAP1) strain. This strain
produces increased amounts of the two toxins, TcdA and TcdB, and also produces a binary
toxin. Increased toxin production occurs because of mutations in genes involved in toxin
expression (McDonald, Killgore et al. 2005). Infection by the NAP1 strain is a significant
predictor of severe CDI, which can result in some of the more severe symptoms mentioned
above (See, Mu et al. 2014). However, others have suggested that strain type does not predict
outcome, so results are mixed at best (Walk, Micic et al. 2012). Research regarding the
relationship between community onset, community associated CDI (CA-CDI) and strain type
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suggested that a majority of infections that originate in the community are caused by the NAP1
strain (Limbago, Long et al. 2009).
A case of CA-CDI is defined as a toxin positive assay for an individual without a
documented healthcare exposure in the last twelve weeks. A healthcare exposure is defined as
a hospital or long term care facility stay. CDI incidence and severity have clearly increased, but
more specifically, CA-CDI has also become more common. Recently, it has been estimated that
approximately 25% of all total CDI cases are defined as CA-CDI, though the percentage tends to
vary depending on the population (Norén, Åkerlund et al. 2004, Kutty, Woods et al. 2010, Lessa
2013). The incidence of CA-CDI has been estimated to be as high as 40 cases per 100,000
population (Khanna, Pardi et al. 2011, Lessa 2013).
CA-CDI incidence also increased in individuals not considered to be high risk for the
disease, including younger individuals and individuals without underlying illness (Pituch 2009,
Kuntz, Chrischilles et al. 2011). Risk factors for CA-CDI and modes of acquisition of the pathogen
may be different compared to that of nosocomial CDI. Some individuals with CA-CDI have
displayed traditional risk factors for CDI, such as increased age and prior antibiotic use (Kutty,
Woods et al. 2010). In other instances, only a subset of individuals displayed risk factors that
are unique to CA-CDI, including exposure to a hospitalized individual, outpatient surgical
procedure, or antibiotic use greater than four weeks prior to onset of symptoms (Fellmeth,
Yarlagadda et al. 2010). Similarly, proton pump inhibitor was considered by some to be a risk
factor for CA-CDI (Dial, Delaney et al. 2005). Others insisted that proton pump inhibitor use is
not a risk factor for CA-CDI (Wilcox, Mooney et al. 2008, Naggie, Miller et al. 2011). Relying on
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traditional risk factors to identify new CA-CDI cases may result in missed diagnoses (Wilcox,
Mooney et al. 2008).
Modes of pathogen transmission and acquisition might differ for individuals with CACDI. Toxigenic strains have been isolated from infected individuals, their homes, asymptomatic
healthcare personnel, sewage, soil, domesticated animals, and store-bought meat products
(Hafiz 1974, Kim, Fekety et al. 1981, Songer and Anderson 2006, Songer, Trinh et al. 2009,
Hoover and Rodriguez-Palacios 2013). Infected individuals may acquire the pathogen via
contact with one or more of these potential sources, leading to CA-CDI. Increased
asymptomatic carriage of the pathogen in the community may be another cause of increased
CA-CDI incidence (Bauer, Goorhuis et al. 2008).
Present Study
The goal of this study is to characterize CA-CDI in New Haven County, Connecticut. In addition
to providing census tract level incidence of CA-CDI, geospatial clusters of infection, if present
are also revealed. A demographic description of CA-CDI by census tract will be provided.
Combining surveillance and socioeconomic data will improve understanding of the economic
contribution to health. To my knowledge, the relationship between socioeconomic status and
CA-CDI incidence has not been examined. Area-based socioeconomic factors can also be
powerful predictors of health outcomes. Areas of high socioeconomic status will have the
lowest proportion of individuals living in poverty and a higher proportion of individuals with
advanced education. Uneducated individuals are more likely to be uninsured and thus less likely
to receive adequate healthcare (Monheit and Vistnes 2000). Although the risk factors of CA-CDI
and non-CA-CDI may differ, prior antibiotic use is still a significant predictor of CA-CDI
7

(McFarland, Clarridge et al. 2007). Use of prescribed antibiotics such as fluoroquinolones
clindamycin, and penicillins may be higher in individuals with increased healthcare access.
Individuals living in wealthier census tracts have better access to healthcare, and have the
insurance that enables affordable access to care (Monheit and Vistnes 2000, Adler and
Newman 2002). I hypothesize that there will be higher incidence rates of CA-CDI in areas of
higher socioeconomic status.
Microbiologic Review
Pathogenesis
An exhaustive review of Clostridium difficile was completed in 1974, though its relevance as a
human pathogen was still not understood (Hafiz 1974). It was not until 1978, after an extensive
four year study, that Clostridium difficile infection (CDI) in humans was linked to
pseudomembranous colitis (PMC) (Bartlett, Chang et al. 1978). Initially, Staphylococcus aureus
was believed to be the cause of antibiotic associated PMC, but, after the discovery of
cytotoxicity in tissue cultures and reproduction of colitis in hamster models, CDI was confirmed
to be the cause (Bartlett, Chang et al. 1978). After the link between CDI and PMC was revealed,
research on CDI in humans increased dramatically. Within the next decade, clinical features and
toxigenesis had been carefully described (Tedesco, Gurwith et al. 1978, Burdon, Brown et al.
1979, Mogg, Burdon et al. 1979, Peikin, Galdibini et al. 1980, Lyerly, Krivan et al. 1988)
Clostridium difficile spores, like many other bacterial spores, survive a variety of
environmental conditions and chemical treatments, but are inactivated by sporicidal agents
(Lawley, Clare et al. 2009). Ingestion of spores, passage through the acidic environment of the
stomach, and passage into the intestinal column results in the development of microfilimental
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projections on the normally smooth outer surface of the spore, which promotes attachment to
the intestinal microvilli (Panessa-Warren, Tortora et al. 2007). Spores then germinate, allowing
vegetative cells to multiply. The mucus layer is penetrated and these cells eventually adhere to
enterocytes via a combination of flagellation and adhesins. At this stage colonization begins
and virulence factors that promote colonization, such as cysteine protease, s-layer proteins,
and flagellar components, are released by the bacteria. Sooner after, toxin production begins.
Study of the toxins has either confirmed or built upon previous studies (Snyder 1937, Hafiz
1974, Lyerly, Krivan et al. 1988). Both Toxin A (TcdA) and Toxin B (TcdB) are
glucosyltransferases, which act to transfer a UDP-glucose to GTPases in the cell. Action of TcdA
and TcdB induces morphological changes in the cell by disrupting cell signaling (Dawson,
Valiente et al. 2009). The fluid secretion and mucosal damage that occurs due to TcdA and TcdB
can result in diarrhea and PMC.
In addition to these two toxins, an additional factor has been identified. Binary toxin,
also referred to as Clostridium difficile transferase (CDT), is found in a smaller proportion of
strains. CDTa and CDTb, the two components of the toxin, combine cytotoxicity in vitro (Geric,
Carman et al. 2006). Although the binding site of CDT in the human body is unknown, the toxin
has been found in several epidemic strains. It has been suggested that the toxin may improve
bacterial adherence to the intestinal epithelium by increasing the presence of microtubules on
the surface of the bacterial surface (Schwan, Stecher et al. 2009).
Diagnosis
After initial disease manifestation, symptoms such as multiple aqueous diarrhea episodes per
day, fever, abdominal cramps, dehydration, and malnourishment can occur. The first test for
9

presence of CDI used was a tissue culture that utilized antitoxin to neutralize TcdA and TcdB.
Since this test is highly sensitive and specific, it was considered one of the best methods for
detecting CDI (Bartlett, Chang et al. 1978). Unfortunately it was time and labor intensive, so
alternative methods were eventually developed. Stool culture is highly effective, though it is
cost and labor-intensive. When possible, it is the preferred method of diagnosis because, when
conducted on selective media, the infecting strain can be recovered and analyzed. This may
become increasingly important as we try to understand the incidence and prevalence of
infection by the NAP1 strain. Immune enzyme assays are a quick diagnosis method though
there is high variability in the sensitivity and specificity of this method (Walker, Ruane et al.
1986). The test is simple, so it is often used, though in combination with a more robust
detection method. Polymerase chain reaction is a highly sensitive and specific method that can
also be used. Laboratory findings must always be considered with the prevailing symptoms for
the patient in mind.
Treatment
Due to success with the use of oral vancomycin in treating enterocolitis, it was and continues to
be used to treat PMC (Cohen, Gerding et al. 2010). The drug was approved by the Food and
Drug Administration in the 1980’s and approved for use in the treatment of CDI (Wilson, Silva et
al. 1981). It has since remained the only FDA approved drug for the treatment of CDI. Side
effects of vancomycin use, including kidney damage, can be serious and more likely in the
elderly.
Since there is a risk of becoming infected by vancomycin-resistant enterococcus species
as a result of treatment, injected metronidazole has become the treatment of choice for
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individuals with less severe CDI (Bartlett 2002). Oral metronidazole is also preferred for its
reduced cost in comparison to oral vancomycin (Bartlett 2002). The effectiveness of
metronidazole versus vancomycin has been researched. Some suggest that there is no
significant difference between the effectiveness of the two treatment methods (Zar,
Bakkanagari et al. 2007). Others suggest that vancomycin is a more effective treatment option
(Musher, Aslam et al. 2005). However, vancomycin resistant enterococcal infection may occur
(Gerding 1997). In addition, individuals who took metronidazole were more likely to have
recurrent infections (Musher, Aslam et al. 2005). Even though these two methods have proven
viable, there are instances in which both drugs may prove ineffective. Individuals with severe
symptoms may not respond appropriately to therapy (McPherson, Rees et al. 2006). Strains
resistant to at least one of these two drugs have been discovered. In these instances, failure of
initial therapies may necessitate hospitalization, where fidaxomicin or intravenous
immunoglobulin can be administered (McPherson, Rees et al. 2006, Louie, Miller et al. 2011).
Methods
At the Connecticut Emerging Infections Program (CT-EIP), active population-based CDI
surveillance is ongoing. CT-EIP is one component of the Centers for Disease Control and
Prevention (CDC) supported network of 10 surveillance sites scattered throughout the country.
Active surveillance began at CT-EIP in 2009, with 23 towns in New Haven and Litchfield county
serving as the catchment area. From 2011 to 2013, New Haven County served as the catchment
area for CDI surveillance. Diagnostic tests for CDI were generally performed in individuals
exhibiting symptoms such as diarrhea. Laboratory confirmed, toxin-positive CDI cases,
excluding those in individuals under one year of age, were reported to the CT-EIP. Via medical
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record review, several variables were collected for each patient, including medical history and
current underlying conditions, antibiotic use, demographic information, and full address.
CDI cases were classified as either incident or recurrent cases based on a basic set of
criteria. Incident CDI was either the first toxin positive CDI for a patient or subsequent CDI that
occurred at least eight weeks after the most recent CDI toxin-positive test. Recurrent CDI was a
case that occurred within 8 weeks of the most recent CDI toxin-positive test. CDI cases are
further classified by onset status as they are collected. Healthcare facility onset cases (HCFO)
were defined as those with a CDI positive specimen sample four or more days after admission
to an acute or long term healthcare facility. Community onset (CO) cases were defined as those
with a CDI positive specimen sample less than four days after admission to a health care facility.
CO cases were further characterized as community onset, healthcare facility associated (COHFA) or community onset, community associated (CO-CA) cases. CO-HFA cases were defined as
those with a documented healthcare exposure (i.e. healthcare facility discharge or residence at
a long term care facility), and CO-CA cases were defined as those that did not have a healthcare
exposure in the prior three months. For the purposes of this study CO-CA cases will be referred
to as CA-CDI.
Demographic information for the population of New Haven County was downloaded via
the Factfinder portal of the United States Census Bureau (United States Census Bureau).
Datasets from the 5-year estimates of the 2012 American Community Survey and the 2010
Decennial Census Summary File 1 were obtained. Population by age, sex, and race/ethnicity as
well as total population figures per census tract in New Haven County were collected from the
decennial census. Poverty rate, or proportion of individuals that lived below the federal poverty
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line in the last 12 months, were collected for each census tract from the American Community
Survey. Health disparities, which impact disease burden, are often reflected in socioeconomic
inequities. Census tract level data are thought to be most sensitive to socioeconomic gradients
in health (Krieger, Chen et al. 2003, Krieger, Chen et al. 2005). Area-based socioeconomic
status will be estimated using the proportion of individuals living under the federal poverty line.
This variable, named percent below poverty for purposes of this study, is thought to accurately
depict the relationship between socioeconomic status and many health outcomes for both the
total population and by race group (Krieger, Chen et al. 2003, Krieger, Chen et al. 2005). The
census tract level poverty rate was split into four groups: <5%, ≥5 to 9.99%, ≥10 to 19.99%, and
≥20% of the total population living under the poverty line (Krieger, Chen et al. 2003, Krieger,
Chen et al. 2005). For the purposes of this study, these four groups will be referred to as census
tract poverty groups.
This study used CDI surveillance data collected from January, 2011 to October, 2013. All
recurrent CDI cases were excluded from the analysis, though additional cases that occurred in
the same patient were not excluded if confirmations of toxin positivity were separated by more
than eight weeks. Cases that were not classified as community associated were also excluded.
Patients with incomplete or invalid demographic information were excluded.
To analyze these data, the home addresses of patients were geocoded using Arcmap
10.1. Geocoding was conducted to determine latitude and longitude coordinates and a spatial
join was conducted to associate each patient with a census tract. Using SAS 9.2 (SAS Institute
Inc, Cary, NC), the proportion of individuals living under the federal poverty line for each census
tract was linked to each patient. Using population data from the 2010 decennial census, the
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population of New Haven County was described by age, sex, race, and poverty. CA-CDI
incidence rates were determined by census tract with 2010 decennial census data used as the
denominator for incidence calculations. Unadjusted CA-CDI incidence rates by sex, race, spatial
location, and poverty rate were also calculated.
A spatial analysis of CA-CDI was conducted in SatScan 9.3 (Martin Kulldorff, Harvard
School of Medicine). Cartesian coordinates from geocoded cases were used in the analysis. A
purely spatial, Poisson regression model was chosen. The shapefile output of the spatial
analysis was joined to a Map of New Haven County to visualize the location of significant spatial
clusters.
Using Epi Info 7 (Centers for Disease Control and Prevention, Atlanta, GA), chi-square
test for trend was conducted to assess the relationship between CDI incidence and percent
below poverty by census tract. Statistical analysis methods were in accordance with those of
the Public Health Disparities Geocoding Project (Krieger et al). Statistical test results were
considered significant if the p-value was less than 0.05.
Results
From August 1, 2009, to October 16, 2013, a total of 5607 incident cases of CDI were captured
by Emerging Infections Program surveillance among New Haven County residents aged over 1
year. Of these 5607 incident cases, 5491, or 97.9% were successfully geocoded. Of these
geocoded cases, 4342 occurred from 2011 to 2013. 1106 of those 4342, or 25.5% of all CDI,
were classified as CA-CDI cases.
Table 1 lists descriptive features of the New Haven county population, including the
distribution of race, sex, age groups and total population of individuals by census tract poverty
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group. Mean annual CA-CDI incidence was significantly different for the five age groups.
(ANOVA: P<0.01). Mean annual incidence by race/ethnicity was also significantly different
(ANOVA: P<0.01). Hispanics had the lowest mean annual CA-CDI incidence at 19.84 per 100,000
individuals, and Non-Hispanic Whites had the highest incidence at 43.06 per 100,000
individuals. Mean Annual incidence was significantly different for females and males (53.21 per
100,000 individuals compared to 30.59 per 100,000 individuals, respectively, (T-test: P<0.01).
Test for trend revealed that mean annual CA-CDI incidence increased as census tract poverty
decreased (Chi-square test for trend: P=0.021).
CA-CDI annual incidence is given, stratified by census tract poverty group, in figure 1.
Overall trends for incidence by census tract poverty were significant in 2011 (Chi-square test for
trend: P=0.014), but not significant for 2012 (Chi-square test for trend: P=0.724) and 2013 (Chisquare test for trend: P=0.230). At 56.54 cases per 100,000 population, the highest incidence of
CA-CDI occurred in 2013 among in census tract poverty group with less than 5% of the total
population living in poverty. In 2012, CA-CDI incidence was also highest in the census tract
poverty group with less than 5% of the total population living in poverty, with 51.91 cases per
100,000 population. In contrast, the census tract poverty group with the highest incidence in
2011 was the ≥5 to 10% group, with 52.80 cases per 100,000 population.
When CA-CDI incidence was further stratified by age, race-ethnicity, and sex, additional
trends were revealed. In figure 2, age groups were further stratified by census tract poverty
group. In the 45-64 years old age group, mean annual CA-CDI incidence increased as the
proportion of individuals living under the federal poverty line per census tract increased (Chisquare test for trend P<0.01). In the 5-17 age group, mean annual CA-CDI incidence decreased
15

as the proportion of individuals living under the federal poverty line per census tract increased
(Chi-square test for trend: all P<0.01). Tests for trend were non-significant in the 1-4, 18-44, and
65+ age groups (Chi-square tests for trend: P=0.207, P=0.164, and P=0.224, respectively). CACDI incidence was highest in the oldest individuals living in the census tracts with the highest
proportion of individuals living under the federal poverty line at 149.34 per 100,000 individuals.
Table 2 describes the population distribution by age group, given in proportions of the
total age group population, in the four census tract poverty groups. Chi-square tests for trend
revealed that the proportion of total population decreased as census tract poverty increased
(chi-square test for trend: all P<0.01). The odds of living in the poorest census tract compared
to the wealthiest census tracts was 0.173 for individuals aged 65 and above and 0.226 for
individuals aged 45-64. The odds ratio was much higher in the youngest age group. Individuals
aged 1-4 were only 0.823 times as likely to live in the poorest census tracts compared to the
wealthiest census tracts.
In figure 3, race/ethnicity groups were further stratified by census tract poverty group.
Due to missing data, only 1038 of the 1106 eligible CA-CDI cases were used in this analysis. For
Non-Hispanic Blacks, Non-Hispanic Whites, and Hispanics, CA-CDI incidence increased as the
proportion of individuals living under the federal poverty line per census tract increased;
however, tests for trend revealed that relationships were non-significant (Chi-square test for
trend: P=0.072, P=0.287, P=0.433, respectively). CA-CDI incidence was highest in the NonHispanic Whites living in the census tracts with the highest proportion of individuals living
under the federal poverty line at 48.66 per 100,000 individuals.
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Table 3 describes the population distribution by race/ethnicity group, given in
proportions of the total race/ethnicity group population, in the four census tract poverty
groups. For Hispanic and non-Hispanic Black individuals, chi-square tests for trend revealed that
the proportion of total population increased as census tract poverty increased (chi-square test
for trend: all P<0.01). For non-Hispanic Whites, chi-square tests for trend revealed that the
proportion of total population decreased as census tract poverty increased (chi-square test for
trend: all P<0.01). Compared to living in the wealthiest census tracts, the odds of living in the
poorest census tracts was 8.86 for non-Hispanic Blacks, 6.82 for Hispanics, and 0.091 for nonHispanic Whites.
In figure 4, sex groups were further stratified by census tract poverty group. For males
and females, CA-CDI incidence decreased as the proportion of individuals living under the
federal poverty line per census tract increased, though for both groups this trend was nonsignificant (chi square tests for trend: P=0.092, P=0.107, respectively). As mentioned previously,
there was a significant difference in mean annual CA-CDI incidence for males and females (TTest: P<0.01). Females had a higher mean annual incidence at 53.21 cases per 100,000
population. When CA-CDI was stratified by sex, the highest incidence of CA-CDI occurred in
females living in census tracts with the lowest proportion of individuals living under the federal
poverty line at 58.8 per 100,000 individuals.
Six spatial clusters of infection were discovered, though only one, the largest of all
discovered, was statistically significant (p<0.05). This cluster had a 7.25 kilometer radius and
covered 8 different census tracts within its border. 58.27 per 100,000 population CA-CDI cases
were expected to occur per year within the borders of this cluster, but 67.9 cases per 100,000
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individuals per year actually occurred, yielding a relative risk of infection of 1.59 for individuals
living within this cluster compared to individuals not living in this cluster. Figure 5 overlays this
cluster on a univariate choropleth map of census tract poverty in New Haven County, allowing
for data visualization.
Discussion
The findings of this study have quantified the burden of CDI in New Haven County. This study
appears to be the first of its kind to analyze the relationship between CA-CDI and area-based
socioeconomic status. The burden of CDI on healthcare systems has been well established,
causing massive increases in healthcare costs and straining resources (Kyne, Hamel et al. 2002,
Miller, Hyland et al. 2002). Linking surveillance and census data will improve surveillance
networks and better understand the burden of CA-CDI. Learning and understanding the
incidence rate of nosocomial and CA-CDI will allow researchers to intervene in areas of high
incidence and respond quickly when an outbreak may be occurring, and inform health policy
decision-making at the local, state and federal levels.
The three-year range in which a variety of incidence calculations were made yielded
important results. This analysis has also revealed the relationship between CDI incidence and
census tract poverty measure, which acted as a proxy for socioeconomic status. I hypothesized
that the census tracts with the highest socioeconomic status would have the highest CDI
incidence. Mean annual incidence was indeed highest in the census tracts with the lowest
proportion of individuals living under the federal poverty line, though the trend of increasing
incidence with decreasing census tract poverty is not as clear as originally anticipated. When
surveillance data from all three years were aggregated and analyzed, CA-CDI incidence
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decreased significantly with increasing census tract poverty. The trend of decreasing CA-CDI
incidence with increasing census tract poverty was significant when restricted to 2011
surveillance data, but not when restricted to 2012 or 2013 surveillance data.
The relationship between area-based socioeconomic status and other health outcomes
has been explored previously, but not for CA-CDI (Krieger, Chen et al. 2002, Yousey-Hindes and
Hadler 2011). With other diseases such as influenza, incidence is expected to increase with
increasing census tract poverty (Yousey-Hindes and Hadler 2011). That is not the case for CACDI. Increased access to broad spectrum prescription antibiotics due to better healthcare
access in wealthier census tracts may indeed drive the trend of increased CA-CDI incidence as
census tract poverty decreases. Additional research will be necessary to determine if
prescription antibiotic use drives CA-CDI incidence in new Haven County.
Mean annual incidence for census tracts in which 5%-9.99% of individuals live under the
federal poverty line was lower than expected for Non-Hispanic Blacks and non-Hispanic Whites.
More importantly, a reversal of trend also occurred in which CA-CDI incidence increased with
increasing census tract poverty for all three race/ethnicity groups. It should be noted, however,
that these trends were not statistically significant. It is possible that the population distribution
of non-Hispanic Whites may have played a role in the reversal of trend. Non-Hispanic Whites in
the poorest census tract poverty group make up only 7.35% of the population. In the
penultimate poorest census tract poverty group, non-Hispanic Whites make up only 19.53% of
the population. The reduced number of individuals in the two poorer census tract poverty
groups contributed to the increased CA-CDI incidence for non-Hispanic White individuals living
in these two census tract poverty groups.
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A substantial proportion of cases of CDI in New Haven County occurred in individuals
aged 65 and above. These individuals made up 42.6% of infections, but only comprised 14.5% of
the total population of New Haven County. The burden of CA-CDI in this segment of the
population is immense. CA-CDI in the 45-64 and 65+ age groups differed from the trend of
mean annual incidence of CA-CDI in that the incidence increases, not decreases, with
decreasing socioeconomic status. Individuals above the age of 45 were much more likely to live
in the wealthier census tracts, leaving a small population of individuals in the poorer census
tract groups. The decreased population in the poorer census tract groups would drive up CACDI incidence. I believe this explains the reversal of trend witnessed in the older age groups and
in non-Hispanic Whites. The impact this may have had on non-Hispanic Blacks and Hispanics is
unknown, since their trends for population distribution differed from that of non-Hispanic
Whites.
The hypothesized trend of increased CA-CDI incidence with decreased census tract
poverty was again evident in males and females. An uneven population distribution by sex in
the census tract poverty groups was not a concern, which further suggests that it may have
impacted incidence calculations by race/ethnicity and age. To truly confirm that this is the case,
adjusted incidence rates must be calculated. This is certainly a direction of future research in
the topic of socioeconomic status and CA-CDI.
The significant cluster covered an area of New Haven County that includes most of
Wallingford and parts of North Haven, Hamden, East Haven, North Branford, and Guilford. Risk
for CA-CDI was elevated in this high wealth area of New Haven County. The greater Wallingford
area is the site of many long term care facilities. The population in this area of New Haven
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County may be older on average than the rest of the county, putting them at greater risk for
CA-CDI. The discovery of this cluster may direct future interventions that aim to reduce the
burden of CA-CDI and also direct future etiologic studies of CA-CDI.
Limitations
In this study antibiotic use among individuals who were infected was not examined. Prior
antibiotic use is widely accepted as one of the primary risk factors for both nosocomial and
community associated infection. Examining antibiotic use in New Haven County and its
interaction with CDI incidence will help public health advocates and medical professionals make
informed choices for diagnosis, treatment, and prevention of CDI. This type of analysis also did
not allow for an examination of disease severity. Strain type was not analyzed, so we do not
currently know if the infecting strain is the NAP1 strain. We also do not know the proportion of
cases in which binary toxin is present, or the proportion of cases that become recurrent. In this
study, the sample size of CA-CDI by census tract was limited, which limits the statistical power
of the analysis conducted in this study. Additional surveillance data would improve statistical
power, so chances are that our understanding of CA-CDI in New Haven County will improve as
surveillance continues. The new Haven population is not a standard population. The uneven
distribution of race ethnicity groups and of the elderly affected incidence calculations, clouding
the true effect of socioeconomic status on CA-CDI incidence.
Conclusions and directions of future research
CA-CDI incidence may be higher in wealthier census tracts compared to poorer census tracts in
New Haven County, but additional research using surveillance data is necessary to confirm that
this is the case.
21

The uneven distribution of the New Haven County population may cloud the true relationship
between area based socioeconomic status and CA-CDI incidence. Calculations of adjusted
incidence rates may help reveal the true relationship.
A significant spatial cluster was discovered in the greater Wallingford area of New Haven
County. CA-CDI incidence is higher than anticipated for that population, so it may prove
beneficial to direct future interventions toward this area of New Haven County.
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Table 1
Demographic description of the New Haven County population

Category

Group

Total at risk
population
Sex

Male
Female

# Cases

Mean Annual
CA-CDI
Incidence

Population

% of total

853257

-

-

-

410361
442896

48.1
51.9

387
719

30.59
53.21

P-value

-

P<0.01
Race

Hispanic
White
Black

127,163
578,002
100,429

14.9
67.5
11.8

80
724
101

19.84
43.06
29.57
P<0.01

Age

1 though 4
5 through 17
18 though 44
45 through 64
65 and up

39,443
144,311
307,590
237,941
123,972

4.6
16.9
36
27.9
14.5

17
26
187
404
472

14.71
5.01
20.19
60.44
129.71
P<0.01

Census tract
poverty

<5%
5%-9.99%
≥10%-19.99%
≥20%

308,237
193,167
193,273
158,580

36.1
22.6
22.7
18.6

442
249
230
185

51.72
46.10
42.80
42.04
P=0.021

This table depicts the New Haven County population by sex, race, age group, and census tract poverty
group. Census tract poverty groups are categorized by the proportion of individuals living under the
federal poverty line in a given census tract. For every census tract that fell into one of four census tract
poverty groups, population figures were aggregated to yield the values above. T-test revealed significant
differences in CA-CDI incidence by sex. ANOVA revealed significant differences in CA-CDI incidence
among race groups and age groups, respectively. Chi-square test for trend revealed significant trend in
CA-CDI incidence, with incidence decreasing as census tract poverty increased.
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Figure 1:

CA-CDI annual incidence by year in New Haven County, further stratified by
census tract poverty group
60

Cases (per 100,000)

50

40

30

20

10

0
2011

2012
<5%

5% -9.99%

10%-19.99%

2013
20%+

Chi-square test for trend revealed a significant downward trend in incidence as census tract poverty
increased for 2011 surveillance data (Chi-square test for trend: P=0.014) but not for 2012 and 2013
surveillance data (Chi-square tests for trend: P=0.724 and P=0.23)
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Figure 2

CA-CDI mean annual incidence by age group in New Haven
County, further stratified by census tract poverty group
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In the 45-64 years old age group, mean annual CA-CDI incidence increased as census tract poverty
increased (Chi-square test for trend P<0.01). In the 5-17 age group, mean annual CA-CDI incidence
decreased as census tract poverty increased (Chi-square test for trend: all P<0.01). Tests for trend were
non-significant in the 1-4, 18-44, and 65+ age groups (Chi-square tests for trend: P=0.207, P=0.164, and
P=0.224, respectively).
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Table 2: Population distribution by age group into census tract poverty groups
Census Tract
Age Group
Poverty
1-4
5-17
18-44
45-64
65+
Group
0.29
0.37
0.30
0.41
0.44
<5%
0.21
0.21
0.21
0.25
0.24
5% -9.99%
0.25
0.21
0.26
0.20
0.20
10%-19.99%
0.25
0.21
0.23
0.14
0.12
20%+
Table 2 describes the population distribution by age group, given in proportions of the total age group
population, in the four census tract poverty groups. Chi-square tests for trend revealed that the
proportion of total population decreased as census tract poverty increased (chi-square test for trend: all
P<0.01). Older individuals were much less likely to live in the poorer census tracts.
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Figure 3:

CA-CDI mean annual incidence by race/ethnicity group in New Haven
County, further stratified by census tract poverty group
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Due to missing data, only 1038 of the 1106 eligible CA-CDI cases were used in this analysis. For
Non-Hispanic Blacks, Non-Hispanic Whites, and Hispanics, CA-CDI incidence increased as the
proportion of individuals living under the federal poverty line per census tract increased;
however, tests for trend revealed that relationships were non-significant (Chi-square test for
trend: P=0.072, P=0.287, P=0.433, respectively). The trend for Non-Hispanic Blacks is near, but
not quite significant, perhaps due to a low number total number of cases.
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Table 3: Population distribution by race/ethnicity group into census tract poverty groups
Census Tract
Race/ethnicity Group
Poverty
Non-Hispanic Black Non-Hispanic White Hispanic
Group
below 5%
0.09
0.47
0.11
5% to 10%
0.12
0.27
0.14
10% to 20%
0.30
0.20
0.29
above 20%
0.48
0.07
0.46

Table 3 describes the population distribution by race/ethnicity group, given in proportions of
the total race/ethnicity group population, in the four census tract poverty groups. For Hispanic
and non-Hispanic Black individuals, chi-square tests for trend revealed that the proportion of
total population increased as census tract poverty increased (chi-square test for trend: all
P<0.01). For non-Hispanic Whites, chi-square tests for trend revealed that the proportion of
total population decreased as census tract poverty increased (chi-square test for trend: all
P<0.01). Only a tiny proportion of Non-Hispanic Whites lived in the poorest census tracts, but
nearly half of Non-Hispanic Blacks and Hispanics lived in the poorest census tracts.
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Figure 4

CA-CDI mean annual incidence by sex in New Haven County, further
stratified by census tract poverty group
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For males and females, CA-CDI incidence decreased as the proportion of individuals living under
the federal poverty line per census tract increased, though for both groups this trend was nonsignificant (chi square tests for trend: P=0.092, P=0.107, respectively). Females had a higher
mean annual incidence at 53.21 cases per 100,000 population. Incidence among females in the
poorest census tracts was still higher than that of men in the wealthiest census tracts.
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Figure 5

Figure 5 displays the only statistically significant spatial cluster on a choropleth map of census tract
poverty in New Haven County. Census tracts with the worst poverty tend to be aggregated around the
New Haven and Waterbury urban areas. The spatial cluster, which is 7.25 kilometer in radius, covered 8
different census tracts within its border. Most of the town of Wallingford is included within the spatial
cluster.

30

References
Adler, N. E. and K. Newman (2002). "Socioeconomic disparities in health: pathways and policies." Health
affairs 21(2): 60-76.
Barbut, F., G. Corthier, Y. Charpak, M. Cerf, H. Monteil, T. Fosse, A. Trevoux, B. De Barbeyrac, Y.
Boussougant and S. Tigaud (1996). "Prevalence and pathogenicity of Clostridium difficile in hospitalized
patients: a French multicenter study." Archives of internal medicine 156(13): 1449.
Bartlett, J. G. (2002). "Antibiotic-associated diarrhea." New England Journal of Medicine 346(5): 334339.
Bartlett, J. G., T. W. Chang, M. Gurwith, S. L. Gorbach and A. B. Onderdonk (1978). "Antibiotic-associated
pseudomembranous colitis due to toxin-producing clostridia." New England Journal of Medicine
298(10): 531-534.
Bauer, M., A. Goorhuis, T. Koster, S. Numan-Ruberg, E. Hagen, S. Debast, E. Kuijper and J. Van Dissel
(2008). "Community-onset Clostridium difficile-associated diarrhoea not associated with antibiotic
usage." Netherlands Journal of Medicine 66: 207-211.
Burdon, D., J. Brown, D. Youngs, Y. Arabi, N. Shinagawa, J. Alexander-Williams, M. Keighley and R.
George (1979). "Antibiotic susceptibility of Clostridium difficile." Journal of Antimicrobial Chemotherapy
5(3): 307-310.
Cohen, S. H., D. N. Gerding, S. Johnson, C. P. Kelly, V. G. Loo, M. L Clifford McDonald, J. Pepin and M. H.
Wilcox (2010). "Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by
the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of
America (IDSA)." infection control and hospital epidemiology 31(5): 431-455.
Dallal, R. M., B. G. Harbrecht, A. J. Boujoukas, C. A. Sirio, L. M. Farkas, K. K. Lee and R. L. Simmons (2002).
"Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications."
Annals of surgery 235(3): 363.
Dawson, L. F., E. Valiente and B. W. Wren (2009). "< i> Clostridium difficile</i>—A continually evolving
and problematic pathogen." Infection, Genetics and Evolution 9(6): 1410-1417.
Dial, S., J. Delaney, A. N. Barkun and S. Suissa (2005). "Use of gastric acid–suppressive agents and the risk
of community-acquired Clostridium difficile–associated disease." Jama 294(23): 2989-2995.
Fellmeth, G., S. Yarlagadda and S. Iyer (2010). "Epidemiology of community-onset< i> Clostridium
difficile</i> infection in a community in the South of England." Journal of infection and public health
3(3): 118-123.
Gerding, D. N. (1997). "Is there a relationship between vancomycin-resistant enterococcal infection and
Clostridium difficile infection?" Clinical infectious diseases 25(Supplement 2): S206-S210.
Geric, B., R. J. Carman, M. Rupnik, C. W. Genheimer, S. P. Sambol, D. M. Lyerly, D. N. Gerding and S.
Johnson (2006). "Binary toxin–producing, large clostridial toxin–negative Clostridium difficile strains are
enterotoxic but do not cause disease in hamsters." Journal of Infectious Diseases 193(8): 1143-1150.
Hafiz, S. (1974). "Clostridium difficile and its toxins [dissertation]. L eeds, United
Kingdom: University of Leeds.".
Hoover, D. G. and A. Rodriguez-Palacios (2013). "Transmission of Clostridium difficile in Foods."
Infectious Disease Clinics of North America 27(3): 675-685.
Khanna, S., D. S. Pardi, S. L. Aronson, P. P. Kammer, R. Orenstein, J. L. St Sauver, W. S. Harmsen and A. R.
Zinsmeister (2011). "The epidemiology of community-acquired Clostridium difficile infection: a
population-based study." The American journal of gastroenterology.
Kim, K.-H., R. Fekety, D. Batts, D. Brown, M. Cudmore, J. Silva and D. Waters (1981). "Isolation of
Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis."
Journal of infectious diseases 143(1): 42-50.
31

Krieger, N., J. T. Chen, P. D. Waterman, D. H. Rehkopf and S. Subramanian (2003). "Race/ethnicity,
gender, and monitoring socioeconomic gradients in health: a comparison of area-based socioeconomic
measures-the public health disparities geocoding project." American journal of public health 93(10):
1655-1671.
Krieger, N., J. T. Chen, P. D. Waterman, D. H. Rehkopf and S. Subramanian (2005). "Painting a truer
picture of US socioeconomic and racial/ethnic health inequalities: the Public Health Disparities
Geocoding Project." American journal of public health 95(2): 312-323.
Krieger, N., J. T. Chen, P. D. Waterman, M.-J. Soobader, S. Subramanian and R. Carson (2002).
"Geocoding and monitoring of US socioeconomic inequalities in mortality and cancer incidence: does
the choice of area-based measure and geographic level matter? the Public Health Disparities Geocoding
Project." American journal of epidemiology 156(5): 471-482.
Kuntz, J. L., E. A. Chrischilles, J. F. Pendergast, L. A. Herwaldt and P. M. Polgreen (2011). "Incidence of
and risk factors for community-associated Clostridium difficile infection: a nested case-control study."
BMC infectious diseases 11(1): 194.
Kutty, P. K., C. W. Woods, A. C. Sena, S. R. Benoit, S. Naggie, J. Frederick, S. Evans, J. Engel and L. C.
McDonald (2010). "Risk Factors for and Estimated Incidence of Community-associated Clostridium
difficile Infection, North Carolina, USA1." Emerging infectious diseases 16(2): 198.
Kyne, L., M. B. Hamel, R. Polavaram and C. P. Kelly (2002). "Health care costs and mortality associated
with nosocomial diarrhea due to Clostridium difficile." Clinical Infectious Diseases 34(3): 346-353.
Lawley, T. D., S. Clare, A. W. Walker, D. Goulding, R. A. Stabler, N. Croucher, P. Mastroeni, P. Scott, C.
Raisen and L. Mottram (2009). "Antibiotic treatment of Clostridium difficile carrier mice triggers a
supershedder state, spore-mediated transmission, and severe disease in immunocompromised hosts."
Infection and immunity 77(9): 3661-3669.
Lessa, F. C. (2013). "Community-associated< i> Clostridium difficile</i> infection: How real is it?"
Anaerobe 24: 121-123.
Limbago, B. M., C. M. Long, A. D. Thompson, G. E. Killgore, G. E. Hannett, N. L. Havill, S. Mickelson, S.
Lathrop, T. F. Jones and M. M. Park (2009). "Clostridium difficile strains from community-associated
infections." Journal of clinical microbiology 47(9): 3004-3007.
Loo, V. G., L. Poirier, M. A. Miller, M. Oughton, M. D. Libman, S. Michaud, A.-M. Bourgault, T. Nguyen, C.
Frenette and M. Kelly (2005). "A predominantly clonal multi-institutional outbreak of Clostridium
difficile–associated diarrhea with high morbidity and mortality." New England Journal of Medicine
353(23): 2442-2449.
Louie, T. J., M. A. Miller, K. M. Mullane, K. Weiss, A. Lentnek, Y. Golan, S. Gorbach, P. Sears and Y.-K.
Shue (2011). "Fidaxomicin versus vancomycin for Clostridium difficile infection." New England Journal of
Medicine 364(5): 422-431.
Lyerly, D. M., H. C. Krivan and T. D. Wilkins (1988). "Clostridium difficile: its disease and toxins." Clinical
microbiology reviews 1(1): 1-18.
McDonald, L. C., G. E. Killgore, A. Thompson, R. C. Owens Jr, S. V. Kazakova, S. P. Sambol, S. Johnson and
D. N. Gerding (2005). "An epidemic, toxin gene–variant strain of Clostridium difficile." New England
Journal of Medicine 353(23): 2433-2441.
McFarland, L. V., J. E. Clarridge, H. W. Beneda and G. J. Raugi (2007). "Fluoroquinolone use and risk
factors for Clostridium difficile-associated disease within a Veterans Administration health care system."
Clinical infectious diseases 45(9): 1141-1151.
McPherson, S., C. J. Rees, R. Ellis, S. Soo and S. J. Panter (2006). "Intravenous immunoglobulin for the
treatment of severe, refractory, and recurrent Clostridium difficile diarrhea." Diseases of the colon &
rectum 49(5): 640-645.

32

Miller, M. A., M. Hyland, M. Ofner-Agostini, M. Gourdeau and M. Ishak (2002). "Morbidity, mortality,
and healthcare burden of nosocomial Clostridium difficile-associated diarrhea in Canadian hospitals."
Infection Control and Hospital Epidemiology 23(3): 137-140.
Mogg, G., D. W. Burdon and M. Keighley (1979). "Oral metronidazole in Clostridium difficile colitis."
British medical journal 2(6185): 335.
Monheit, A. C. and J. P. Vistnes (2000). "Race/ethnicity and health insurance status: 1987 and 1996."
Medical Care Research and Review 57(4 suppl): 11-35.
Musher, D. M., S. Aslam, N. Logan, S. Nallacheru, I. Bhaila, F. Borchert and R. J. Hamill (2005). "Relatively
poor outcome after treatment of Clostridium difficile colitis with metronidazole." Clinical Infectious
Diseases 40(11): 1586-1590.
Naggie, S., B. A. Miller, K. B. Zuzak, B. W. Pence, A. J. Mayo, B. P. Nicholson, P. K. Kutty, L. C. McDonald
and C. W. Woods (2011). "A Case-control Study of Community-associated< i> Clostridium difficile</i>
Infection: No Role for Proton Pump Inhibitors." The American journal of medicine 124(3): 276. e271-276.
e277.
Norén, T., T. Åkerlund, E. Bäck, L. Sjöberg, I. Persson, I. Alriksson and L. Burman (2004). "Molecular
epidemiology of hospital-associated and community-acquired Clostridium difficile infection in a Swedish
county." Journal of Clinical Microbiology 42(8): 3635-3643.
Panessa-Warren, B. J., G. T. Tortora and J. B. Warren (2007). "High resolution FESEM and TEM reveal
bacterial spore attachment." Microscopy and Microanalysis 13(04): 251-266.
Peikin, S., J. Galdibini and J. Bartlett (1980). "Role of Clostridium difficile in a case of nonantibioticassociated pseudomembranous colitis." Gastroenterology 79(5 Pt 1): 948-951.
Pépin, J., L. Valiquette, M.-E. Alary, P. Villemure, A. Pelletier, K. Forget, K. Pépin and D. Chouinard (2004).
"Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of
disease severity." Canadian Medical Association Journal 171(5): 466-472.
Pituch, H. (2009). "< i> Clostridium difficile</i> is no longer just a nosocomial infection or an infection of
adults." International journal of antimicrobial agents 33: S42-S45.
Schwan, C., B. Stecher, T. Tzivelekidis, M. van Ham, M. Rohde, W.-D. Hardt, J. Wehland and K. Aktories
(2009). "Clostridium difficile toxin CDT induces formation of microtubule-based protrusions and
increases adherence of bacteria." PLoS pathogens 5(10): e1000626.
See, I., Y. Mu, J. Cohen, Z. G. Beldavs, L. G. Winston, G. Dumyati, S. Holzbauer, J. Dunn, M. M. Farley and
C. Lyons (2014). "NAP1 strain type predicts outcomes from Clostridium difficile infection." Clinical
Infectious Diseases: ciu125.
Snyder, M. L. (1937). "Further Studies on Bacillus Difficilis (Hall and O'Toole)." Journal of Infectious
Diseases 60(2): 223-231.
Songer, J. G. and M. A. Anderson (2006). "< i> Clostridium difficile</i>: An important pathogen of food
animals." Anaerobe 12(1): 1-4.
Songer, J. G., H. T. Trinh, G. E. Killgore, A. D. Thompson, L. C. McDonald and B. M. Limbago (2009).
"Clostridium difficile in retail meat products, USA, 2007." Emerging infectious diseases 15(5): 819.
Tedesco, F., M. Gurwith, R. Markham, D. Christie and J. Bartlett (1978). "Oral vancomycin for antibioticassociated pseudomembranous colitis." The Lancet 312(8083): 226-228.
United States Census Bureau: Accessed at
http://factfinder2.census.gov/faces/nav/jsf/pages/index.xhtml
Walk, S. T., D. Micic, R. Jain, E. S. Lo, I. Trivedi, E. W. Liu, L. M. Almassalha, S. A. Ewing, C. Ring and A. T.
Galecki (2012). "Clostridium difficile ribotype does not predict severe infection." Clinical infectious
diseases 55(12): 1661-1668.
Walker, R. C., P. J. Ruane, J. E. Rosenblatt, D. M. Lyerly, C. A. Gleaves, T. F. Smith, P. F. Pierce Jr and T. D.
Wilkins (1986). "Comparison of culture, cytotoxicity assays, and enzyme-linked immunosorbent assay for

33

toxin A and toxin B in the diagnosis of< i> Clostridium difficile</i>-related enteric disease." Diagnostic
microbiology and infectious disease 5(1): 61-69.
Wilcox, M., L. Mooney, R. Bendall, C. Settle and W. Fawley (2008). "A case–control study of communityassociated Clostridium difficile infection." Journal of Antimicrobial Chemotherapy 62(2): 388-396.
Wilson, K. H., J. Silva and F. R. Fekety (1981). "Suppression of Clostridium difficile by normal hamster
cecal flora and prevention of antibiotic-associated cecitis." Infection and immunity 34(2): 626.
Yousey-Hindes, K. M. and J. L. Hadler (2011). "Neighborhood socioeconomic status and influenza
hospitalizations among children: New Haven County, Connecticut, 2003-2010." American journal of
public health 101(9).
Zar, F. A., S. R. Bakkanagari, K. Moorthi and M. B. Davis (2007). "A comparison of vancomycin and
metronidazole for the treatment of Clostridium difficile–associated diarrhea, stratified by disease
severity." Clinical Infectious Diseases 45(3): 302-307.

34

